Dr. Crees is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1 Barnes Jewish Hospital Plz
# Div
Saint Louis, MO 63110Phone+1 314-454-8304Fax+1 314-454-5902
Education & Training
Washington University/B-JH/SLCH ConsortiumChief Residency, Internal Medicine, 2018 - 2019- Washington University/B-JH/SLCH ConsortiumInternship, Internal Medicine, 2015 - 2018
University of Illinois College of MedicineClass of 2015
Certifications & Licensure
MO State Medical License 2017 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Inductee Alpha Omega Alpha Honor Medical Society
- Inductee Gold Humanism Honor Society
Clinical Trials
Publications & Presentations
PubMed
- 26 citationsMotixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial.Zachary D Crees, Michael P Rettig, Reyka G Jayasinghe, Keith Stockerl-Goldstein, Sarah M Larson
Nature Medicine. 2023-04-01 - 26 citationsThyroid Cancer Resistance to Vitamin D Receptor Activation Is Associated with 24-Hydroxylase Levels But Not the ff FokI PolymorphismVibha Sharma, Deborah L. Fretwell, Zachary Crees, Anna Kerege, Joshua P. Klopper
Thyroid. 2010-10-01 - 28 citationsOligonucleotides and G-quadruplex Stabilizers: Targeting Telomeres and Telomerase in Cancer TherapyZachary Crees, Jennifer Girard, Zechary Rios, Gregory M. Botting, Kymberly Harrington
Current Pharmaceutical Design. 2014-11-30
Press Mentions
BioLineRx Announces Oral Presentation on Data from Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease at ASH 2024November 5th, 2024- BioLineRx Presents Data from Pivotal GENESIS Trial of Motixafortide plus G-CSF for Stem Cell Mobilization in Multiple Myeloma Patients; NDA Submission Planned in 2022December 17th, 2021
- BioLineRx Provides Highlights from Oral Presentation Delivered at the 63rd American Society of Hematology (ASH) Annual Meeting & ExpositionDecember 17th, 2021
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
